Targeted News Service

GentiBio Receives Grant from Breakthrough T1D and the Helmsley Charitable Trust to Support POLARIS Trial of GNTI-122 in Recently Diagnosed Type 1 Diabetes
January 26, 2026

NEW YORK, Jan. 26 -- Breakthrough T1D (formerly JDRF) a non-profit dedicated to funding type 1 diabetes research, posted the following news release:

* * *

GentiBio Receives Grant from Breakthrough T1D and the Helmsley Charitable Trust to Support POLARIS Trial of GNTI-122 in Recently Diagnosed Type 1 Diabetes

*

BOSTON, Jan. 26, 2026-GentiBio, Inc., a biotechnology company pioneering engineered regulatory T cell (EngTreg) therapies, today announc . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form